Understand the source comparison
Do Peptides Help with Joint Pain — Full Comparison
Before choosing any peptide protocol, understand how each compound differs in mechanism, administration, evidence quality, and practical use. This table distills what matters. BPC-157 Upregulates VEGF and bFGF; promotes angiogenesis and collagen cross-linking
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- Before choosing any peptide protocol, understand how each compound differs in mechanism, administration, evidence quality, and practical use. This table distills what matters.
- BPC-157
- Upregulates VEGF and bFGF; promotes angiogenesis and collagen cross-linking
- Subcutaneous, oral
- 200–500 mcg daily, 4–12 weeks
- Preclinical + early human pilot data
- Strongest mechanistic rationale for ligament and tendon repair; human RCT data limited but consistent with animal models
- TB-500
- Binds actin; modulates inflammatory cytokines (IL-1β, TNF-α); enhances chondrocyte migration
- Subcutaneous injection
- 2–5 mg twice weekly, 4–8 weeks
- Veterinary use established; Phase 2 human trials ongoing
- Demonstrated efficacy in equine tendon injury; human osteoarthritis data promising but not yet peer-reviewed
- Collagen Peptides
- Oral bioavailable dipeptides/tripeptides signal chondrocytes to upregulate collagen synthesis
- Oral (powder/capsule)
- 5–15g daily, minimum 12 weeks
- Multiple RCTs; strongest human evidence base
- Best-supported for long-term use; effect size moderate but reproducible across populations; safe for extended protocols
- Pentosan Polysulfate
- Semi-synthetic glycosaminoglycan analogue; inhibits cartilage-degrading enzymes
- Subcutaneous or IM injection
- 3 mg/kg twice weekly (veterinary); human dosing varies
- FDA-approved for interstitial cystitis; used off-label for joints in equine/canine medicine
- Not a peptide but often compared; anti-catabolic rather than anabolic. Slows degradation but doesn't stimulate repair